Minerva Neurosciences (NASDAQ:NERV) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Analyst Recommendations
This is a breakdown of current recommendations for Minerva Neurosciences and Clovis Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Minerva Neurosciences | 0 | 2 | 3 | 0 | 2.60 |
Clovis Oncology | 2 | 2 | 2 | 0 | 2.00 |
Minerva Neurosciences currently has a consensus price target of $6.75, suggesting a potential upside of 113.61%. Clovis Oncology has a consensus price target of $8.80, suggesting a potential upside of 41.71%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than Clovis Oncology.
Profitability
This table compares Minerva Neurosciences and Clovis Oncology's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Minerva Neurosciences | N/A | -51.19% | -29.75% |
Clovis Oncology | -230.34% | N/A | -57.56% |
Risk & Volatility
Minerva Neurosciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.
Institutional & Insider Ownership
66.3% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 12.0% of Minerva Neurosciences shares are held by company insiders. Comparatively, 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Minerva Neurosciences and Clovis Oncology's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Minerva Neurosciences | N/A | N/A | $-72,180,000.00 | ($1.85) | -1.70 |
Clovis Oncology | $143.01 million | 3.85 | $-400,420,000.00 | ($7.60) | -0.82 |
Minerva Neurosciences has higher earnings, but lower revenue than Clovis Oncology. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Minerva Neurosciences beats Clovis Oncology on 9 of the 13 factors compared between the two stocks.